ArticleBiologics : targets & therapy2013
New and emerging treatments for ulcerative colitis: a focus on vedolizumab.
Article in Biologics : targets & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.World journal of gastroenterology · 2015Pooled it
- Pooled it
- The Dual Role of Neutrophils in Inflammatory Bowel Diseases.Journal of clinical medicine · 2016Review
- Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis.Archives of medical science : AMS · 2016Review
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.Inflammatory bowel diseases · 2015Article
- Biological therapy for ulcerative colitis: an update.World journal of gastroenterology · 2014Review
- New targets for mucosal healing and therapy in inflammatory bowel diseases.Mucosal immunology · 2014Review
- Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?Clinical and experimental gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.